October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress. Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority ...
Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...
Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...
MB-108 shows activity and is well tolerated in recurrent glioblastoma, with preclinical data supporting its combination with ...
Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...
Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.
Combining the checkpoint inhibitor atezolizumab with targeted therapy led to improvements in overall survival in patients ...
Oncology trials often celebrate treatments improving progression-free survival, yet toxicity-related censoring can bias ...
The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback